Quel est le site Web ?

https://www.facebook.com/432202614266447/

IMMUcan

IMMUcan is an (now IHI) project proposing an inclusive immuno-oncology platform.

19/06/2026

Over more than seven years of collaboration, discovery and knowledge-sharing have led to a remarkable scientific legacy.

From more than 30 presentations at major international conferences to a growing portfolio of publications, IMMUcan has contributed valuable insights into tumour-immune interactions while supporting the next generation of cancer researchers.

Importantly, the project's impact will continue beyond its official end. Clinical, molecular and imaging datasets generated through IMMUcan will be made available through recognised data repositories, creating a lasting resource for the global cancer research community and enabling future discoveries in immuno-oncology.

A sincere thank you to all patients, researchers, clinicians and partners who made this journey possible.

Learn more about IMMUcan's research, datasets and scientific outputs: www.immucan.eu

12/05/2026

Good morning from Berlin, where the final IMMUcan General Assembly starts today.

Over the past years, IMMUcan has grown into one of the largest efforts of its kind in Europe to profile the tumour microenvironment across cancer types. It feels like the right moment to look at what this project has actually built: patient cohorts across major cancer types, molecular and cellular profiling, spatial transcriptomics, proteomics, plasma profiling, imaging data, and analyses now moving into publications and reusable resources.

The project brought together clinicians, researchers, data scientists, hospitals, academic centres, industry partners, and patient organisations around one shared question: how can we better understand the tumour microenvironment so future cancer treatment becomes more precise?

Over the next two days, we’ll go through the science, the datasets, the publications, the lessons learned, and the work still needed to make sure the results continue to be useful beyond the project.

There’s always something slightly reflective about a final meeting. You start to see the project not just as a series of results, but as something that took time, coordination, and a lot of collective effort to come together.

05/05/2026

Translational insight starts with integrated data.

A recent medRxiv preprint uses IMMUcan’s multi-modal NSCLC dataset to explore how tumour microenvironment features align with histology, molecular alterations, and clinical variables.

This work highlights the value of combining imaging, genomics, and clinical annotation to support clinically meaningful stratification in lung cancer research.

Read the preprint:
https://www.medrxiv.org/content/10.1101/2025.11.10.25339890v1

IMMUcan samples and data are now open for access, supporting discovery that bridges biology and clinical relevance.

👉 Apply for access: https://immucan.eu/how-to-collaborate

15/04/2026

A bioRxiv preprint introduces Cellohood, a new computational framework for identifying cellular neighbourhoods, developed and validated using IMMUcan imaging datasets.

The study shows how large, harmonised spatial datasets enable reproducible, interpretable discovery of tumour microenvironment organisation using advanced computational approaches.

📄 Read the preprint:
https://www.biorxiv.org/content/10.1101/2025.11.10.687184v1

IMMUcan biosamples and data are designed to support exactly this kind of innovative, cross-disciplinary research.

👉 Learn how to collaborate: https://immucan.eu/how-to-collaborate

09/03/2026

IMMUcan data powering advances in cancer research methods.

A 2025 Cell Reports Methods publication presents scalable, reproducible multi-modal imaging and analysis workflows developed and validated using IMMUcan cancer tissue data.

The study highlights how access to standardised, high-quality samples at scale enables not only biological discovery, but also the development of robust, open-source analytical methods for the wider community.

Read the paper:
https://www.cell.com/cell-reports-methods/fulltext/S2667-2375(25)00206-1

With IMMUcan biosamples now accessible to external researchers, similar method-driven innovation is within reach.

Explore access: https://immucan.eu/how-to-collaborate

17/02/2026

IMMUcan data have already contributed to peer-reviewed, high-impact research, including a 2024 publication in Immunity, one of the leading journals in immunology.

The study explores how CD4⁺ T cell activation distinguishes patient responses to combined PD-L1 and CTLA-4 blockade in head and neck cancer, advancing our understanding of immune mechanisms underlying immunotherapy response.

This work illustrates what becomes possible when deeply annotated human biosamples are combined with rigorous molecular and clinical data.

Read the paper:
https://www.cell.com/immunity/fulltext/S1074-7613(24)00083-9

If your next research depends on robust, trial-grade oncology samples, IMMUcan is open for collaboration.
Explore sample availability & submit a proposal: https://immucan.eu/how-to-collaborate

03/02/2026

High-impact cancer research starts with access to the right samples.

Over the past years, IMMUcan data and biosamples have supported research published in leading journals such as Cancer Research, Immunity, and Cell Reports Methods -, advancing our understanding of tumour–immune interactions, spatial biology, and translational biomarkers.

IMMUcan has opened access to its oncology biosample collection from ~1,400 patients, covering major cancer cohorts including:
▪ Non-small-cell lung cancer (NSCLC)
▪ Renal cell carcinoma (RCC)
▪ Colorectal cancer (CRC)
▪ Triple-negative & HER2+ breast cancer
▪ Head & neck cancer

Available materials include FFPE tumour tissue, tumor and germline DNA/RNA, PBMCs, and plasma/serum suitable for cfDNA analyses, all paired with rich molecular and clinical data and maintained at trial-grade quality with centralised QC.

This is an opportunity for researchers to build on proven, high-impact foundations and accelerate discovery without starting sample collection from scratch.

Explore sample availability and submit your proposal:
https://immucan.eu/how-to-collaborate

09/01/2026

High-quality data drives high-impact discoveries — and IMMUcan is opening the door to one of the largest, most extensively profiled oncology sample collections available.

Researchers can now request access to biosamples from ~1,400 patients across major cancer cohorts, including NSCLC, RCC, CRC, TNBC, HER2+ BC, and head & neck cancer. Available materials range from FFPE blocks and slides to tumor DNA/RNA, germline DNA, PBMCs, and plasma/serum suitable for cfDNA analyses.

All samples come with robust molecular and clinical data, offering a powerful foundation for biomarker discovery, immune profiling, and integrative multi-omics research. Trial-grade quality and centralised QC ensure consistency and reliability.

If you're developing your next analysis or exploring new hypotheses in cancer immunology, this is an opportunity worth acting on.

👉 Explore availability and submit your proposal: https://immucan.eu/how-to-collaborate/

All requests undergo scientific and feasibility review.

19/12/2025

As 2025 comes to a close, we look back with gratitude on the progress IMMUcan has made through the years: from advancing multi-omics data generation to deepening our understanding of the tumour microenvironment, together with an outstanding community of partners.

Thank you to all patients, clinicians, researchers, and collaborators whose commitment continues to make this initiative possible.

We wish you a restful holiday season and a new year filled with health, discovery, and collaboration.

✨ Happy Holidays from the IMMUcan team! ✨

18/12/2025

🔬 IMMUcan at ESMO Immuno-Oncology 2025 | Poster Highlight II

The second IMMUcan poster featured at presented real-world data from the IMMUcan early-stage TNBC cohort. The research focusing on patients treated with neoadjuvant chemo-(immuno) therapy was presented by Camille Goudemant from Institut Jules Bordet.

Over a 5-year period, the team observed:
✅ Evolving neoadjuvant TNBC practices across Europe
✅ Decreasing anthracycline use and increasing use of carboplatin and immunotherapy
✅ Improving pCR rates over time, highest with KEYNOTE-522–like regimens and in tumors with high TIL levels

While survival data are not yet available, surrogate markers such as pCR and TILs provide valuable insights into treatment effectiveness in real-world settings. These data support the feasibility and effectiveness of neoadjuvant chemo-immunotherapy in early TNBC across Europe.

IMMUcan highlights the power of collaborative, data-sharing initiatives that combine clinical outcomes with deep molecular and immune profiling. Ongoing multi-omics analyses will further refine our understanding of TNBC biology and treatment response.

👉 Learn more: www.immucan.eu

Adresse

Petit Bruxelles

Site Web

facebook.com

Notifications

Soyez le premier à savoir et laissez-nous vous envoyer un courriel lorsque IMMUcan publie des nouvelles et des promotions. Votre adresse e-mail ne sera pas utilisée à d'autres fins, et vous pouvez vous désabonner à tout moment.